Experts discuss recent data on next generation sequencing and germline testing in patients with advanced and metastatic cancer.
EP. 1: Defining Germline Sequencing and Incidental Germline Findings
Mark Robson, MD, and a panel of experts discuss key terminology and definitions related to tumor and germline sequencing.
EP. 2: Tumor-Normal Matched Sequencing and Platforms Utilized for Tumor Profiling
Mark Robson, MD, reviews data from a recent abstract on incidental germline findings detected by tumor-normal matched sequencing and the panelists share which platforms they utilize for tumor profiling.
EP. 3: Experience with Interpreting Somatic Reports
A panel of experts share their experiences with interpreting information on somatic reports and provide recommendations for verifying results.
EP. 4: Identification of Patients for Germline Testing
The panel of experts provide insight on how they identify patients for germline testing.
EP. 5: Role of ctDNA in Germline Testing
Mark Robson, MD; John Henson, MD; Ashley Ross, MD, PhD; and Dana Farengo Clark, MS, LCGC, discuss the evolving role of circulating tumor DNA (ctDNA) in germline testing.
EP. 6: Operational Processes and Challenges
Mark Robson, MD; John Henson, MD; Ashley Ross, MD, PhD; and Dana Farengo Clark, MS, LCGC, discuss operational processes and techniques for counseling patients about germline testing.
Experts Weigh in on Topic of Frontline Osimertinib Alone or With Chemo in EGFR-Mutant NSCLC
Dr Sands on the Evolving Role of ADCs in SCLC Management
Dr Hirsch on the Treatment of NRG1 Fusion+ NSCLC
MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer